Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Kintara Therapeutics, Inc. (KTRA)

3.44   0.06 (1.78%) 06-09 12:58
Open: 3.31 Pre. Close: 3.38
High: 3.48 Low: 3.31
Volume: 3,482 Market Cap: 6(M)

Technical analysis

as of: 2023-06-09 1:16:01 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 4.56     One year: 5.34
Support: Support1: 2.82    Support2: 2.35
Resistance: Resistance1: 3.91    Resistance2: 4.57
Pivot: 3.16
Moving Average: MA(5): 3.28     MA(20): 3.11
MA(100): 4.17     MA(250): 6.57
MACD: MACD(12,26): 0     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 45.2     %D(3): 39.1
RSI: RSI(14): 55.1
52-week: High: 20  Low: 2.7
Average Vol(K): 3-Month: 41 (K)  10-Days: 22 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ KTRA ] has closed below upper band by 11.2%. Bollinger Bands are 63.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.55 - 3.57 3.57 - 3.58
Low: 3.2 - 3.22 3.22 - 3.23
Close: 3.35 - 3.38 3.38 - 3.4

Company Description

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

Headline News

Thu, 08 Jun 2023
Is Kintara Therapeutics Inc (KTRA) Stock a Smart Investment Thursday? - InvestorsObserver

Fri, 02 Jun 2023
Why Guidewire Software Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday’s M - Benzinga

Thu, 11 May 2023
Kintara Therapeutics Announces Fiscal 2023 Third Quarter ... - PR Newswire

Fri, 05 May 2023
Healthcare Stocks on the Move Friday: OMI, IBRX, NERV, ABOS, SNGX, DMTK, BIO, KTRA - InvestorsObserver

Tue, 18 Apr 2023
What is the Market's View on Kintara Therapeutics Inc (KTRA) Stock's Price and Volume Trends Tuesday? - InvestorsObserver

Tue, 14 Feb 2023
Kintara Therapeutics Announces Fiscal 2023 Second Quarter Financial Results and Provides Corporate Update - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 2 (M)
Shares Float 2 (M)
% Held by Insiders 0.6 (%)
% Held by Institutions 4.1 (%)
Shares Short 14 (K)
Shares Short P.Month 22 (K)

Stock Financials

EPS -11.06
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -4.06
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -108.2
Return on Equity (ttm) -254.5
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -9.97
Qtrly Earnings Growth 0
Operating Cash Flow -15 (M)
Levered Free Cash Flow -8 (M)

Stock Valuations

PE Ratio -0.31
PEG Ratio 0
Price to Book value -0.85
Price to Sales 0
Price to Cash Flow -0.38

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.